New drug cocktails tested for advanced cancers: hope or hype?

NCT ID NCT03307785

Completed Disease control Sponsor: Tesaro, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib, TSR-042, bevacizumab, carboplatin, paclitaxel, pemetrexed, nab-paclitaxel, TSR-022
What this could lead to: If successful, this could point toward safer, more effective drug combinations for advanced cancers, potentially improving disease control.
What could go wrong: This is a very early (Phase 1) dose-finding study with only 60 participants. The combinations may cause serious side effects and may not work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER METASTATIC CANCER NEOPLASMS NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER STAGE IIIB SOLID TUMOR

Contacts and locations

Locations

GSK Investigational Site

Scottsdale, Arizona, 85258, United States
GSK Investigational Site

Encinitas, California, 92024, United States
GSK Investigational Site

San Marcos, California, 92069, United States
GSK Investigational Site

Sarasota, Florida, 34232, United States
GSK Investigational Site

Canton, Ohio, 44718, United States
GSK Investigational Site

Cleveland, Ohio, 44106, United States
GSK Investigational Site

Nashville, Tennessee, 37203, United States
GSK Investigational Site

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.